首页> 外文OA文献 >Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy
【2h】

Entry Inhibitors Directed Towards Glycoprotein gp120: An Overview on a Promising Target for HIV-1 Therapy

机译:针对糖蛋白gp120的进入抑制剂:HIV-1治疗的有希望的目标的概述。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In spite of the unquestionable positive impact of HAART in the treatment of HIV infection, the discovery and development of novel agents directed towards other targets of the replicative cycle of the virus that differ from those targeted by the clinically approved drugs, emerges nowadays as an imperative need. The blockade of HIV entry is a highly promising strategy against the pathogen and glycoprotein gp120 is a central actor in this process. This review discusses the current status in the research of anti-HIV agents targeting specifically the envelope protein gp120. The diverse approaches devoted to the achievement of therapeutic agents against gp120 currently under study are organized and analyzed critically according to their specific mechanism of inhibition and structural features.
机译:尽管HAART在治疗HIV感染方面具有毫无疑问的积极影响,但如今,当务之急是发现和开发针对与病毒复制周期其他目标不同的新型药物,这些目标与临床批准药物所针对的目标不同。需要。阻止HIV进入是一种针对病原体的极有前途的策略,糖蛋白gp120在此过程中扮演着重要角色。这篇综述讨论了针对特定包膜蛋白gp120的抗HIV药物的研究现状。目前正在研究中的各种针对gp120的治疗剂的实现方法都是根据其具体的抑制机制和结构特征进行严格组织和分析的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号